Literature DB >> 24994843

Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia.

David J Irwin1, Corey T McMillan2, EunRan Suh2, John Powers2, Katya Rascovsky2, Elisabeth M Wood2, Jon B Toledo2, Steven E Arnold2, Virginia M-Y Lee2, Vivianna M Van Deerlin2, John Q Trojanowski2, Murray Grossman2.   

Abstract

OBJECTIVE: To determine the prognostic utility of tauopathy-associated single nucleotide polymorphisms (SNPs) in sporadic behavioral-variant frontotemporal dementia (bvFTD).
METHODS: Eighty-one patients with sporadic bvFTD were genotyped for tauopathy-associated SNPs at rs8070723 (microtubule-associated protein tau [MAPT]) and rs1768208 (myelin-associated oligodendrocyte basic protein [MOBP]). We performed a retrospective case-control study comparing age at onset and disease duration between carriers of ≥1 polymorphism allele and noncarriers for these SNPs. Subanalyses were performed for autopsied subgroups with tauopathy (n = 20) and TDP-43 proteinopathy (n = 12). To identify a potential biological basis for disease duration, neuroimaging measures of white matter integrity were evaluated (n = 37).
RESULTS: Carriers of risk allele (T) in rs1768208 (i.e., MOBP RA+) had a shorter median disease duration (TC/TT = 5.5 years, CC = 9.5 years; p = 0.02). This was also found in the subset of cases with autopsy-confirmed tauopathies (p = 0.04) but not with TDP-43 proteinopathies (p > 0.1). By comparison, polymorphisms at rs8070723 (MAPT) had no effect on disease duration (p > 0.1), although carriers of protective allele (G) in rs8070723 had a younger median age at onset (AG/GG = 54.5 years, AA = 58 years; p < 0.01). MOBP RA+ patients had increased radial diffusivity in the superior corona radiata and midbrain, and reduced fractional anisotropy in the superior corona radiata as well as superior and inferior longitudinal fasciculi compared with noncarriers (p < 0.01).
CONCLUSIONS: The rs1768208 risk polymorphism in MOBP may have prognostic value in bvFTD. MOBP RA+ patients have more severe white matter degeneration in bvFTD that may contribute to shorter disease duration. Future studies are needed to help confirm these findings.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24994843      PMCID: PMC4141997          DOI: 10.1212/WNL.0000000000000668

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

1.  Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND.

Authors:  K A Josephs; D S Knopman; J L Whitwell; B F Boeve; J E Parisi; R C Petersen; D W Dickson
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

2.  Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia.

Authors:  Isabelle Le Ber; Eric Guedj; Audrey Gabelle; Patrice Verpillat; Magali Volteau; Catherine Thomas-Anterion; Marielle Decousus; Didier Hannequin; Pierre Véra; Lucette Lacomblez; Agnès Camuzat; Mira Didic; Michèle Puel; Jean-Albert Lotterie; Véronique Golfier; Anne-Marie Bernard; Martine Vercelletto; Christine Magne; François Sellal; Izzie Namer; Bernard-François Michel; Jacques Pasquier; François Salachas; Jean Bochet; Alexis Brice; Marie-Odile Habert; Bruno Dubois
Journal:  Brain       Date:  2006-11       Impact factor: 13.501

3.  Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion.

Authors:  Johannes Brettschneider; Vivianna M Van Deerlin; John L Robinson; Linda Kwong; Edward B Lee; Yousuf O Ali; Nathaniel Safren; Mervyn J Monteiro; Jon B Toledo; Lauren Elman; Leo McCluskey; David J Irwin; Murray Grossman; Laura Molina-Porcel; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-03-18       Impact factor: 17.088

4.  Unexpected abundance of pathological tau in progressive supranuclear palsy white matter.

Authors:  Victoria Zhukareva; Sonali Joyce; Teresa Schuck; Vivianna Van Deerlin; Howard Hurtig; Roger Albin; Sid Gilman; Steven Chin; Bruce Miller; John Q Trojanowski; Virginia M-Y Lee
Journal:  Ann Neurol       Date:  2006-09       Impact factor: 10.422

5.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy.

Authors:  M Baker; I Litvan; H Houlden; J Adamson; D Dickson; J Perez-Tur; J Hardy; T Lynch; E Bigio; M Hutton
Journal:  Hum Mol Genet       Date:  1999-04       Impact factor: 6.150

6.  Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.

Authors:  Günter U Höglinger; Nadine M Melhem; Dennis W Dickson; Patrick M A Sleiman; Li-San Wang; Lambertus Klei; Rosa Rademakers; Rohan de Silva; Irene Litvan; David E Riley; John C van Swieten; Peter Heutink; Zbigniew K Wszolek; Ryan J Uitti; Jana Vandrovcova; Howard I Hurtig; Rachel G Gross; Walter Maetzler; Stefano Goldwurm; Eduardo Tolosa; Barbara Borroni; Pau Pastor; Laura B Cantwell; Mi Ryung Han; Allissa Dillman; Marcel P van der Brug; J Raphael Gibbs; Mark R Cookson; Dena G Hernandez; Andrew B Singleton; Matthew J Farrer; Chang-En Yu; Lawrence I Golbe; Tamas Revesz; John Hardy; Andrew J Lees; Bernie Devlin; Hakon Hakonarson; Ulrich Müller; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-06-19       Impact factor: 38.330

Review 7.  The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).

Authors:  Adam L Boxer; Michael Gold; Edward Huey; William T Hu; Howard Rosen; Joel Kramer; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; George Jackson; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven S Khachaturian; Margaret Sutherland; Susan Abushakra; Joseph Lewcock; Robert Farese; Robert O Kenet; Frank Laferla; Steve Perrin; Steve Whitaker; Lawrence Honig; Marsel M Mesulam; Brad Boeve; Murray Grossman; Bruce L Miller; Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2012-10-10       Impact factor: 21.566

8.  Clinical features and survival of 3R and 4R tauopathies presenting as behavioral variant frontotemporal dementia.

Authors:  William T Hu; Joseph E Parisi; David S Knopman; Bradley F Boeve; Dennis W Dickson; J Eric Ahlskog; Ronald C Petersen; Keith A Josephs
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Oct-Dec       Impact factor: 2.703

9.  Factors associated with survival probability in autopsy-proven frontotemporal lobar degeneration.

Authors:  S X Xie; M S Forman; J Farmer; P Moore; Y Wang; X Wang; C M Clark; H B Coslett; A Chatterjee; S E Arnold; H Rosen; J H T Karlawish; V M Van Deerlin; V M-Y Lee; J Q Trojanowski; M Grossman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-07-05       Impact factor: 10.154

10.  A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.

Authors:  Jon B Toledo; Vivianna M Van Deerlin; Edward B Lee; EunRan Suh; Young Baek; John L Robinson; Sharon X Xie; Jennifer McBride; Elisabeth M Wood; Theresa Schuck; David J Irwin; Rachel G Gross; Howard Hurtig; Leo McCluskey; Lauren Elman; Jason Karlawish; Gerard Schellenberg; Alice Chen-Plotkin; David Wolk; Murray Grossman; Steven E Arnold; Leslie M Shaw; Virginia M-Y Lee; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-24       Impact factor: 21.566

View more
  10 in total

1.  Occupational attainment influences survival in autopsy-confirmed frontotemporal degeneration.

Authors:  Lauren Massimo; Jarcy Zee; Sharon X Xie; Corey T McMillan; Katya Rascovsky; David J Irwin; Ann Kolanowski; Murray Grossman
Journal:  Neurology       Date:  2015-04-22       Impact factor: 9.910

2.  Cell-autonomous requirement of TDP-43, an ALS/FTD signature protein, for oligodendrocyte survival and myelination.

Authors:  Jia Wang; Wan Yun Ho; Kenneth Lim; Jia Feng; Greg Tucker-Kellogg; Klaus-Armin Nave; Shuo-Chien Ling
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-29       Impact factor: 11.205

3.  Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.

Authors:  David J Irwin; Nigel J Cairns; Murray Grossman; Corey T McMillan; Edward B Lee; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-12-31       Impact factor: 17.088

4.  ALS-Plus syndrome: non-pyramidal features in a large ALS cohort.

Authors:  Leo McCluskey; Shannon Vandriel; Lauren Elman; Vivianna M Van Deerlin; John Powers; Ashley Boller; Elisabeth McCarty Wood; John Woo; Corey T McMillan; Katya Rascovsky; Murray Grossman
Journal:  J Neurol Sci       Date:  2014-07-18       Impact factor: 3.181

5.  Common genetic variation is associated with longitudinal decline and network features in behavioral variant frontotemporal degeneration.

Authors:  Lauren Massimo; Lior Rennert; Sharon X Xie; Christopher Olm; Jessica Bove; Vivianna Van Deerlin; David J Irwin; Murray Grossman; Corey T McMillan
Journal:  Neurobiol Aging       Date:  2021-08-03       Impact factor: 4.673

Review 6.  Precision Medicine for Frontotemporal Dementia.

Authors:  Mu-N Liu; Chi-Ieong Lau; Ching-Po Lin
Journal:  Front Psychiatry       Date:  2019-02-21       Impact factor: 4.157

Review 7.  Genetic architecture of common non-Alzheimer's disease dementias.

Authors:  Rita Guerreiro; Elizabeth Gibbons; Miguel Tábuas-Pereira; Celia Kun-Rodrigues; Gustavo C Santo; Jose Bras
Journal:  Neurobiol Dis       Date:  2020-05-19       Impact factor: 5.996

8.  Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.

Authors:  Wouter van Rheenen; Aleksey Shatunov; Annelot M Dekker; Russell L McLaughlin; Frank P Diekstra; Sara L Pulit; Rick A A van der Spek; Urmo Võsa; Simone de Jong; Matthew R Robinson; Jian Yang; Isabella Fogh; Perry Tc van Doormaal; Gijs H P Tazelaar; Max Koppers; Anna M Blokhuis; William Sproviero; Ashley R Jones; Kevin P Kenna; Kristel R van Eijk; Oliver Harschnitz; Raymond D Schellevis; William J Brands; Jelena Medic; Androniki Menelaou; Alice Vajda; Nicola Ticozzi; Kuang Lin; Boris Rogelj; Katarina Vrabec; Metka Ravnik-Glavač; Blaž Koritnik; Janez Zidar; Lea Leonardis; Leja Dolenc Grošelj; Stéphanie Millecamps; François Salachas; Vincent Meininger; Mamede de Carvalho; Susana Pinto; Jesus S Mora; Ricardo Rojas-García; Meraida Polak; Siddharthan Chandran; Shuna Colville; Robert Swingler; Karen E Morrison; Pamela J Shaw; John Hardy; Richard W Orrell; Alan Pittman; Katie Sidle; Pietro Fratta; Andrea Malaspina; Simon Topp; Susanne Petri; Susanne Abdulla; Carsten Drepper; Michael Sendtner; Thomas Meyer; Roel A Ophoff; Kim A Staats; Martina Wiedau-Pazos; Catherine Lomen-Hoerth; Vivianna M Van Deerlin; John Q Trojanowski; Lauren Elman; Leo McCluskey; A Nazli Basak; Ceren Tunca; Hamid Hamzeiy; Yesim Parman; Thomas Meitinger; Peter Lichtner; Milena Radivojkov-Blagojevic; Christian R Andres; Cindy Maurel; Gilbert Bensimon; Bernhard Landwehrmeyer; Alexis Brice; Christine A M Payan; Safaa Saker-Delye; Alexandra Dürr; Nicholas W Wood; Lukas Tittmann; Wolfgang Lieb; Andre Franke; Marcella Rietschel; Sven Cichon; Markus M Nöthen; Philippe Amouyel; Christophe Tzourio; Jean-François Dartigues; Andre G Uitterlinden; Fernando Rivadeneira; Karol Estrada; Albert Hofman; Charles Curtis; Hylke M Blauw; Anneke J van der Kooi; Marianne de Visser; An Goris; Markus Weber; Christopher E Shaw; Bradley N Smith; Orietta Pansarasa; Cristina Cereda; Roberto Del Bo; Giacomo P Comi; Sandra D'Alfonso; Cinzia Bertolin; Gianni Sorarù; Letizia Mazzini; Viviana Pensato; Cinzia Gellera; Cinzia Tiloca; Antonia Ratti; Andrea Calvo; Cristina Moglia; Maura Brunetti; Simona Arcuti; Rosa Capozzo; Chiara Zecca; Christian Lunetta; Silvana Penco; Nilo Riva; Alessandro Padovani; Massimiliano Filosto; Bernard Muller; Robbert Jan Stuit; Ian Blair; Katharine Zhang; Emily P McCann; Jennifer A Fifita; Garth A Nicholson; Dominic B Rowe; Roger Pamphlett; Matthew C Kiernan; Julian Grosskreutz; Otto W Witte; Thomas Ringer; Tino Prell; Beatrice Stubendorff; Ingo Kurth; Christian A Hübner; P Nigel Leigh; Federico Casale; Adriano Chio; Ettore Beghi; Elisabetta Pupillo; Rosanna Tortelli; Giancarlo Logroscino; John Powell; Albert C Ludolph; Jochen H Weishaupt; Wim Robberecht; Philip Van Damme; Lude Franke; Tune H Pers; Robert H Brown; Jonathan D Glass; John E Landers; Orla Hardiman; Peter M Andersen; Philippe Corcia; Patrick Vourc'h; Vincenzo Silani; Naomi R Wray; Peter M Visscher; Paul I W de Bakker; Michael A van Es; R Jeroen Pasterkamp; Cathryn M Lewis; Gerome Breen; Ammar Al-Chalabi; Leonard H van den Berg; Jan H Veldink
Journal:  Nat Genet       Date:  2016-07-25       Impact factor: 41.307

9.  Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis.

Authors:  Katerina Placek; Michael Benatar; Joanne Wuu; Evadnie Rampersaud; Laura Hennessy; Vivianna M Van Deerlin; Murray Grossman; David J Irwin; Lauren Elman; Leo McCluskey; Colin Quinn; Volkan Granit; Jeffrey M Statland; Ted M Burns; John Ravits; Andrea Swenson; Jon Katz; Erik P Pioro; Carlayne Jackson; James Caress; Yuen So; Samuel Maiser; David Walk; Edward B Lee; John Q Trojanowski; Philip Cook; James Gee; Jin Sha; Adam C Naj; Rosa Rademakers; Wenan Chen; Gang Wu; J Paul Taylor; Corey T McMillan
Journal:  EMBO Mol Med       Date:  2020-12-03       Impact factor: 14.260

10.  MOBP rs616147 Polymorphism and Risk of Amyotrophic Lateral Sclerosis in a Greek Population: A Case-Control Study.

Authors:  Ioannis Liampas; Vasileios Siokas; Athina-Maria Aloizou; Christos Bakirtzis; Zisis Tsouris; Anastasia Nousia; Grigorios Nasios; Dimitra Papadimitriou; Panagiotis Liakos; Dimitrios P Bogdanos; Georgios M Hadjigeorgiou; Efthimios Dardiotis
Journal:  Medicina (Kaunas)       Date:  2021-12-07       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.